Visão geral da empresa
Cellectis S.A. operates as a clinical stage biotechnological company dedicated to developing products based on gene-editing technologies, specifically focusing on a portfolio of allogeneic chimeric antigen receptor T-cells product candidates within the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, a domain characterized by significant research and development expenditures where firms often trade without current profitability while pursuing breakthrough therapies. In terms of scale, Cellectis S.A. holds a market capitalization of $352.07M and generates annual revenue of $79.59M with a workforce comprising 224 employees. These financial figures indicate that the company maintains a substantial valuation relative to its current revenue base, a common characteristic in biotechnology where future pipeline potential is priced in rather than historical earnings, suggesting the market places high value on its development stage assets despite the absence of traditional profit generation.
Saúde financeira
The company reported a revenue of $79.59M over the trailing twelve months, yet this revenue generated a net income of $-67,593,000, revealing a cost structure where operating expenses significantly outweigh top-line income. This negative net income is further reflected in an EBITDA of $-21,750,000, indicating that even before interest and taxes, the core business operations are currently burning cash to fund clinical trials and development activities. Free cash flow stands at $-25,282,376, which signifies that the company is currently in a cash consumption phase typical for clinical stage biotechs, utilizing available liquidity to sustain operations rather than distributing surplus to shareholders. The margin profile is stark, with a gross margin of 100.0% suggesting that cost of goods sold is negligible or zero for this stage of production, contrasted by an operating margin of -142.1% and a profit margin of -84.9%, both of which highlight the heavy burden of general and administrative expenses required to advance clinical candidates. On the balance sheet, the company holds $206.38M in cash against $86.69M in debt, resulting in a debt-to-equity ratio of 114.22, which indicates a leveraged position relative to equity but maintains a conservative stance on absolute debt levels given the cash buffer. Liquidity is supported by a current ratio of 1.62, demonstrating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin of safety. Finally, the return on equity is -65.3% and the return on assets is -5.8%, metrics that reveal management is currently deploying capital to generate value through future product approvals rather than realizing immediate returns on invested equity or assets.
Avaliação de valorização
The valuation metrics present a unique picture for a loss-making biotechnology firm, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of -5.65, the latter implying that the market expects earnings to remain negative or for the company to continue operating at a loss in the near term. The price-to-book ratio is 3.34, indicating that the market values the company at a premium of more than three times its book value, reflecting high confidence in the intrinsic value of its intellectual property and clinical pipeline. Alternative valuation metrics such as the price-to-sales ratio of 4.42 and an EV/EBITDA of -6.18 suggest that the stock is priced based on revenue generation potential and asset backing rather than current profitability or earnings multiples. Price action has seen significant volatility, with the stock trading between a 52-week high of $5.48 and a 52-week low of $1.17. Assuming the current market price is near the mid-to-lower end of this range relative to historical data points, the stock trades at a discount to its recent high but commands a significant premium above its recent low, highlighting the binary nature of biotech valuation where small changes in clinical data can drive large price swings. The beta value of 2.71 indicates that the stock is highly volatile, moving with approximately 2.7 times the magnitude of the broader market, which serves as a warning of substantial price fluctuations that can occur independent of fundamental business progress.
Growth & Income
Cellectis S.A. experienced a revenue growth rate of -19.5% year over year, while earnings growth is marked as N/A due to the lack of positive earnings in the prior period. This contraction in revenue without a corresponding positive earnings growth trajectory implies that the company is still in a resource-intensive development phase where sales declines may be attributed to strategic shifts or the natural cycle of clinical trial funding rather than a failure of the business model. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it reinvests all available earnings, including retained cash, directly into research, development, and clinical trials to accelerate the path to market approval. The overall growth and income profile for Cellectis S.A. is defined by a lack of current profitability and dividend distribution, relying entirely on external capital and internal cash reserves to fuel future expansion and product commercialization.